IL277575B2 - Antibodies to chelated radionuclides - Google Patents
Antibodies to chelated radionuclidesInfo
- Publication number
- IL277575B2 IL277575B2 IL277575A IL27757520A IL277575B2 IL 277575 B2 IL277575 B2 IL 277575B2 IL 277575 A IL277575 A IL 277575A IL 27757520 A IL27757520 A IL 27757520A IL 277575 B2 IL277575 B2 IL 277575B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (52)
1. An antibody comprising an antigen binding site specific for DOTAM-lead (Pb) chelate, wherein said antigen binding site comprises at least: a) a heavy chain CDR1; b) heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO:2); c) heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO:3); d) light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO:4); e) a light chain CDR2; f) light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO:6), wherein numbering is according to Kabat.
2. The antibody of claim 1, wherein: a) the heavy chain CDR1 comprises the amino acid sequence GFSLSTYSMS (SEQ ID NO:1) or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 1, optionally conservative substitutions; and/or e) the light chain CDR2 comprises the amino acid sequence QASKLAS (SEQ ID NO: 5) or a variant thereof having at least 1, 2 or 3 substitutions in SEQ ID NO: 5, optionally conservative substitutions.
3. The antibody of any one of the preceding claims, wherein the antigen binding site comprises: a) heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO:1); b) heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO:2); c) heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO:3); d) light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO:4); e) light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO: 5); and f) light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO:6).
4. The antibody according to any one of the preceding claims, which is human, chimeric or humanized. 40 277575/ 2
5. An antibody according to any one of the preceding claims, wherein the antigen binding site further comprises a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO 9, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 7 or SEQ ID NO: 9.
6. An antibody according to any one of the preceding claims, wherein the antigen binding site further comprises a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 10, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 8 or 10.
7. An antibody according to any one of the preceding claims, wherein the antigen binding site comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID No. 7 and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 8.
8. An antibody according to any one of the preceding claims, wherein the antigen binding site comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID No. 9 and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 10.
9. An antibody according to any one of the preceding claims, wherein the antigen binding site binds to the Pb-DOTAM chelate with a Kd value of 100pM, 50pM, 20pM, 10pM, 5pM, 1pM or less, as measured by KinExA (kinetic exclusion) assay.
10. An antibody according to any one of the preceding claims, wherein the antigen binding site binds to the Pb-DOTAM chelate and to a Bi-DOTAM chelate, and wherein the ratio of Kd values for the Bi-DOTAM chelate/Pb-DOTAM chelate is in the range of 0.1-10 or 1-10, as measured by KinExA (kinetic exclusion) assay.
11. An antibody according to any one of the preceding claims, which is a whole antibody, or which is an antibody fragment selected from the group consisting of an Fv, Fab, Fab', Fab’-SH, F(ab'), diabody, linear antibody, or single-chain antibody molecule. 277575/ 2
12. An antibody according to any one of the preceding claims, wherein the antibody is coupled to a moiety which binds specifically to a target antigen.
13. The antibody according to claim 12, wherein the target antigen is a tumour specific antigen.
14. The antibody according to claim 12 or 13, which is a multispecific or bispecific antibody.
15. The multispecific or bispecific antibody of claim 14, wherein the tumour specific antigen is selected from the group consisting of CEA, HERand CD20 .
16. The multispecific or bispecific antibody of claim 15, wherein the tumour specific antigen is carcinoembryonic antigen (CEA).
17. The multispecific or bispecific antibody of any one of claims 14 to 16, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for the Pb-DOTAM chelate and at least one antigen binding site specific for CEA, and wherein the antigen binding site specific for CEA comprises a heavy chain comprising at least one, two or three heavy chain CDRs, wherein: d) heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: e) heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: f) heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 13; and/or the antigen binding site specific for CEA comprises a light chain comprising at least one, two or three light chain CDRs: wherein: a) light chain CDR1 comprises the amino acid sequence SEQ ID NO: 14; b) light chain CDR2 comprises the amino acid sequence SEQ ID NO:15; c) light chain CDR3 comprises the amino acid sequence SEQ ID NO: 16.
18. The multispecific or bispecific antibody of claim 17, wherein the antigen binding site for CEA comprises at least one, two, three, four, five, or six (i.e., all) of the CDRs selected from: a) heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11; 40 277575/ 2 b) heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12; c) heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 13; d) light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14; e) light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15; f) light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16.
19. The multispecific or bispecific antibody of any one of claims 14 to 18, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for the Pb-DOTAM chelate and at least one antigen binding site specific for CEA, and wherein the antigen binding site specific for CEA comprise i) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 17; and/or ii) a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 18, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 18.
20. The multispecific or bispecific antibody of claim 19, wherein the antigen binding site specific for CEA comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 17 and/or a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 18.
21. The multispecific or bispecific antibody according to any one of claims 14 or 15, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for ERBB2, and wherein the antigen binding site specific for ERBB2 comprises at least one, two, three, four, five, or six CDRs selected from (a)CDR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:29; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:30; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:31; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:32; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:33. 277575/ 2
22. The multispecific or bispecific antibody according to any one of claims 14, 15 or 21, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for the Pb-DOTAM chelate and at least one antigen binding site specific for ERBB2, and wherein the antigen binding site specific for ERBB2 comprises i) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 34, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 34; and/or ii) a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 35.
23. The multispecific or bispecific antibody according to claim 22, wherein the antigen binding site specific for ERBB2 comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 34 and/or a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 35.
24. The multispecific or bispecific antibody according to any one of claims 14 or 15, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for CD20, and wherein the antigen binding site specific for CD20 comprises at least one, two, three, four, five, or six CDRs selected from (a)CDR-H1 comprising the amino acid sequence of SEQ ID NO:39; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:40; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:41; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:42; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:43; and (f) CDR-Lcomprising the amino acid sequence of SEQ ID NO:44.
25. The multispecific or bispecific antibody according to any one of claims 14, 15 or 24, wherein the multispecific or bispecific antibody comprises at least one antigen binding site specific for the Pb-DOTAM chelate and at least one antigen binding site specific for CD20, and wherein the antigen binding site specific for CD20 comprises i) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 45, or a variant thereof comprising an amino acid sequence having at 40 277575/ 2 least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 45; and/or ii) a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 46, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 46.
26. The multispecific or bispecific antibody according to claim 25, wherein the antigen binding site specific for CD20 comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 45 and/or a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 46.
27. The multispecific or bispecific antibody of any one of claims 14 to 26, which comprises an Fc region.
28. The multispecific or bispecific antibody of claim 27, wherein the Fc region is engineered to reduce effector function.
29. The multispecific or bispecific antibody of claim 28, wherein the Fc region by substitution of one or more of Fc region residues 234, 235, 238, 265, 269, 270, 297, 327 and/or 329.
30. The multispecific or bispecific antibody of any one of claims 27-29, comprising a full-length antibody comprising a first and second antibody heavy chain and a first and second antibody light chain, wherein the first heavy chain and the first light chain assemble to form an antigen binding site for the first antigen, and wherein the second heavy chain and second light chain assemble to form an antigen binding site for the second antigen, wherein either the first or the second antigen is the Pb-DOTAM chelate, and the other is the target antigen.
31. The multispecific or bispecific antibody of claim 30, further comprising an additional antigen binding moiety for the first antigen.
32. The multispecific or bispecific antibody of claim 31, comprising: a full length antibody comprising a first and second antibody heavy chain and a first and second antibody light chain, wherein the first heavy chain and the first light chain assemble to form a Fab comprising an antigen binding site for the first antigen, and wherein the second heavy chain and 40 277575/ 2 second light chain assemble to form a cross-Fab comprising an antigen binding site for the second antigen; and wherein either the first or second antibody heavy chain is fused via a linker to a polypeptide comprising a CH1 and VH domain, and said first polypeptide is assembled with a second polypeptide comprising a CL and VL, such that the first and second polypeptide assemble to form a Fab comprising an antigen binding site for the first antigen.
33. The multispecific or bispecific antibody of claim 32, wherein the N-terminus of the second antibody heavy chain is fused via a linker to said first polypeptide.
34. The multispecific or bispecific antibody of any one of claims 27 to 29, comprising: i) a full length antibody comprising an antigen binding site for a first antigen; and ii) at least a second heavy chain variable domain and second light chain variable domain which together form an antigen binding site for a second antigen, wherein either the first or the second antigen is the Pb-DOTAM chelate, and the other is the target antigen.
35. The multispecific or bispecific antibody of claim 34, comprising a full length antibody comprising an antigen binding site for the first antigen, wherein the N- or C-terminus of one of the heavy chains is linked via a polypeptide linker to a first polypeptide and wherein the first polypeptide associates with a second polypeptide to form a Fab or a cross-Fab comprising a binding site for the second antigen.
36. The multispecific or bispecific antibody of claim 35, which comprises: i) a first polypeptide consisting of a VH domain and a CH1 domain, which is associated with a second polypeptide consisting of a VL and CL domain; or ii) a first polypeptide consisting of a VL domain and a CH1 domain, which is associated with a second polypeptide consisting of a VH and CL domain; or iii) a first polypeptide consisting of a VH domain and a CL domain, which is associated with a second polypeptide consisting of a VL and CHdomain; 40 277575/ 2 such that the first and second polypeptide together form an antigen binding site for the second antigen.
37. The multispecific or bispecific antibody of claim 36, which comprises a full length antibody comprising an antigen binding site for the first antigen, wherein the C-terminus of one of the heavy chains is linked via a polypeptide linker to a first polypeptide consisting of a VL domain and a CH1 domain, which is associated with a second polypeptide consisting of a VH and CL domain.
38. A multispecific or bispecific antibody according to claim 34, comprising: a) a full length antibody specifically binding a first antigen and consisting of two antibody heavy chains and two antibody light chains; b) a polypeptide consisting of i) an antibody heavy chain variable domain (VH); or ii) an antibody heavy chain variable domain (VH) and an antibody constant domain (CH1); or iii) an antibody heavy chain variable domain (VH) and an antibody light chain constant domain (CL);, wherein said polypeptide is fused with the N-terminus of the VH domain via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; c) a polypeptide consisting of i) an antibody light chain variable domain (VL); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL); or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1); wherein said polypeptide is fused with the N-terminus of the VL domain via a peptide linker to the C-terminus of the other of the two heavy chains of said full-length antibody; and wherein the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site to a second antigen, wherein either the first or the second antigen is the Pb-DOTAM chelate and the other is the target antigen.
39. The multispecific or bispecific antibody according to any one of claims 30-38, wherein the first antigen is the target antigen and the second antigen is the Pb-DOTAM chelate. 277575/ 2
40. The multispecific or bispecific antibody according to claim 39, wherein the first antigen is CEA.
41. A multispecific or bispecific antibody according to claim 40, which further comprises: a) a full length antibody specifically binding CEA and consisting of two antibody heavy chains and two antibody light chains; wherein the heavy chains have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1- 450 of SEQ ID NO: 22 or 23; and wherein the light chains have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO 21; b) a polypeptide consisting of i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 7; or ii) said antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable of SEQ ID NO: 7 and an antibody heavy chain constant domain (CH1); and iii) said antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable of SEQ ID NO: 7 and an antibody light chain constant domain (CL), wherein said polypeptide is fused with the N-terminus of the VH domain via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; and c) a polypeptide consisting of i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 8; or ii) said antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable of SEQ ID NO: 8 and an antibody light chain constant domain (CL); or iii) said antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable of SEQ ID NO: 8 and an antibody heavy chain constant domain (CH1);, 40 277575/ 2 wherein said polypeptide is fused with the N-terminus of the VL domain via a peptide linker to the C-terminus of the other of the two heavy chains of said full-length antibody; wherein the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site to Pb-DOTAM chelate.
42. A multispecific or bispecific antibody according to claim 40, which further comprises: a) a full length antibody specifically binding CEA and consisting of two antibody heavy chains and two antibody light chains; wherein the heavy chains have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1 to 450 or SEQ ID NO: 19 or 20; and wherein the light chains have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: b) a polypeptide consisting of i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 9; or ii) said antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable of SEQ ID NO: 9 and an antibody heavy chain constant domain (CH1); or iii) said antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable of SEQ ID NO: 9 and an antibody light chain constant domain (CL);, wherein said polypeptide is fused with the N-terminus of the VH domain via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; c) a polypeptide consisting of i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 10; or ii) said antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable of SEQ ID NO: 10 and an antibody light chain constant domain (CL); or iii) said antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light 277575/ 2 chain variable of SEQ ID NO: 10 and an antibody heavy chain constant domain (CH1);, wherein said polypeptide is fused with the N-terminus of the VL domain via a peptide linker to the C-terminus of the other of the two heavy chains of said full-length antibody; and wherein the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site to the Pb-DOTAM chelate.
43. A multispecific or bispecific antibody according to claim 40, which comprises: i) a first heavy chain comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 22, ii) a second heavy chain comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 23, and iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21.
44. A multispecific or bispecific antibody according to claim 43, which comprises: i) a first heavy chain having the amino acid sequence of SEQ ID NO: 22; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 23; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21.
45. A multispecific or bispecific antibody according to claim 40, which comprises: i) a first heavy chain having an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 19, ii) a second heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 20, iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21.
46. A multispecific or bispecific antibody according to claim 45, which comprises: 277575/ 2 i) a first heavy chain having the amino acid sequence of SEQ ID NO: 19; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 20; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21.
47. An isolated polynucleotide or an isolated set of polynucleotides encoding an antibody according to any one of the preceding claims.
48. A vector comprising the polynucleotide or the set of polynucleotides according to claim 47.
49. A kit or a composition comprising a set of vectors, together comprising the set of polynucleotides according to claim 47.
50. The vector of claim 48 or the set of vectors of claim 49, which are expression vectors.
51. A prokaryotic or eukaryotic host cell comprising an isolated polynucleotide or an isolated set of polynucleotides according to claim 47, optionally comprising the vector of claim 48 or the set of vectors of claim 49.
52. A method of producing an antibody according to any one of claims 1 to 46, comprising expressing the antibody from the host cell of claim 51.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658468P | 2018-04-16 | 2018-04-16 | |
| PCT/EP2019/059856 WO2019201959A1 (en) | 2018-04-16 | 2019-04-16 | Antibodies for chelated radionuclides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277575A IL277575A (en) | 2020-11-30 |
| IL277575B1 IL277575B1 (en) | 2025-07-01 |
| IL277575B2 true IL277575B2 (en) | 2025-11-01 |
Family
ID=66476592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277575A IL277575B2 (en) | 2018-04-16 | 2019-04-16 | Antibodies to chelated radionuclides |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20220389116A1 (en) |
| EP (2) | EP4406607A3 (en) |
| JP (3) | JP7475283B2 (en) |
| KR (1) | KR102884852B1 (en) |
| CN (1) | CN112261952A (en) |
| AR (1) | AR115053A1 (en) |
| AU (1) | AU2019254537B2 (en) |
| BR (1) | BR112020021061A2 (en) |
| CA (1) | CA3096338A1 (en) |
| CL (1) | CL2020002680A1 (en) |
| CR (1) | CR20200548A (en) |
| DK (1) | DK3781200T3 (en) |
| ES (1) | ES2985352T3 (en) |
| FI (1) | FI3781200T3 (en) |
| HR (1) | HRP20241013T1 (en) |
| HU (1) | HUE067622T2 (en) |
| IL (1) | IL277575B2 (en) |
| LT (1) | LT3781200T (en) |
| MA (1) | MA52545B1 (en) |
| MX (1) | MX2020010954A (en) |
| MY (1) | MY207044A (en) |
| PE (1) | PE20210442A1 (en) |
| PL (1) | PL3781200T3 (en) |
| PT (1) | PT3781200T (en) |
| RS (1) | RS65753B1 (en) |
| SG (1) | SG11202010066TA (en) |
| SI (1) | SI3781200T1 (en) |
| TW (1) | TWI874314B (en) |
| UA (1) | UA130541C2 (en) |
| WO (1) | WO2019201959A1 (en) |
| ZA (1) | ZA202006121B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (en) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | Treating cancer by blocking the interaction between TIM-3 and its ligands |
| KR20210124308A (en) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | Anti-GAL3 antibodies and uses thereof |
| AR119382A1 (en) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
| MX2022014786A (en) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Methods of treating inflammatory diseases by blocking galectin-3. |
| WO2022008688A1 (en) * | 2020-07-10 | 2022-01-13 | F. Hoffmann-La Roche Ag | Antibodies which bind to cancer cells and target radionuclides to said cells |
| PE20240690A1 (en) | 2021-01-12 | 2024-04-10 | Hoffmann La Roche | SPLIT ANTIBODIES THAT BIND TO CANCER CELLS AND DIRECT RADIONUCLIDES TO THESE CELLS |
| CN116744981A (en) * | 2021-01-13 | 2023-09-12 | 豪夫迈·罗氏有限公司 | combination therapy |
| AU2022207624A1 (en) * | 2021-01-13 | 2023-07-13 | F. Hoffmann-La Roche Ag | Combination therapy |
| JP2024546810A (en) | 2021-12-15 | 2024-12-26 | ワイ-マブス セラピューティクス, インコーポレイテッド | scFvs and antibodies with reduced multimerization |
| WO2024099526A1 (en) | 2022-11-08 | 2024-05-16 | Y-Mabs Therapeutics, Inc. | Bispecific antibody compounds |
| IL330142A (en) | 2024-02-20 | 2026-08-01 | F Hoffmann La Roche Ag | Novel pre-targeting antibodies and uses thereof |
| WO2026041568A1 (en) | 2024-08-20 | 2026-02-26 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and dotam |
| WO2026082710A1 (en) | 2024-10-16 | 2026-04-23 | F. Hoffmann-La Roche Ag | Small molecule-inducible recombinant receptors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016130539A2 (en) * | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| WO2017194438A1 (en) * | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2943299A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
| WO2016102536A1 (en) * | 2014-12-23 | 2016-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza |
| WO2016126950A1 (en) * | 2015-02-05 | 2016-08-11 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| JP7044700B2 (en) * | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific anti-CEAXCD3 T cell activating antigen binding molecule |
| PL3781201T3 (en) * | 2018-04-16 | 2026-02-23 | Orano Med Manufacturing SAS | Antibodies to chelated radionuclides and clarifying agents |
-
2019
- 2019-04-16 KR KR1020207032824A patent/KR102884852B1/en active Active
- 2019-04-16 MY MYPI2020005339A patent/MY207044A/en unknown
- 2019-04-16 MX MX2020010954A patent/MX2020010954A/en unknown
- 2019-04-16 ES ES19723014T patent/ES2985352T3/en active Active
- 2019-04-16 JP JP2020556869A patent/JP7475283B2/en active Active
- 2019-04-16 SI SI201930792T patent/SI3781200T1/en unknown
- 2019-04-16 FI FIEP19723014.7T patent/FI3781200T3/en active
- 2019-04-16 HR HRP20241013TT patent/HRP20241013T1/en unknown
- 2019-04-16 CR CR20200548A patent/CR20200548A/en unknown
- 2019-04-16 AU AU2019254537A patent/AU2019254537B2/en active Active
- 2019-04-16 SG SG11202010066TA patent/SG11202010066TA/en unknown
- 2019-04-16 CA CA3096338A patent/CA3096338A1/en active Pending
- 2019-04-16 RS RS20240810A patent/RS65753B1/en unknown
- 2019-04-16 WO PCT/EP2019/059856 patent/WO2019201959A1/en not_active Ceased
- 2019-04-16 US US17/048,073 patent/US20220389116A1/en not_active Abandoned
- 2019-04-16 TW TW108113285A patent/TWI874314B/en active
- 2019-04-16 AR ARP190101005A patent/AR115053A1/en unknown
- 2019-04-16 CN CN201980038709.1A patent/CN112261952A/en active Pending
- 2019-04-16 DK DK19723014.7T patent/DK3781200T3/en active
- 2019-04-16 IL IL277575A patent/IL277575B2/en unknown
- 2019-04-16 EP EP24169799.4A patent/EP4406607A3/en active Pending
- 2019-04-16 BR BR112020021061-7A patent/BR112020021061A2/en unknown
- 2019-04-16 LT LTEPPCT/EP2019/059856T patent/LT3781200T/en unknown
- 2019-04-16 PL PL19723014.7T patent/PL3781200T3/en unknown
- 2019-04-16 HU HUE19723014A patent/HUE067622T2/en unknown
- 2019-04-16 PE PE2020001551A patent/PE20210442A1/en unknown
- 2019-04-16 EP EP19723014.7A patent/EP3781200B1/en active Active
- 2019-04-16 PT PT197230147T patent/PT3781200T/en unknown
- 2019-04-16 MA MA52545A patent/MA52545B1/en unknown
- 2019-04-16 UA UAA202007212A patent/UA130541C2/en unknown
-
2020
- 2020-10-02 ZA ZA2020/06121A patent/ZA202006121B/en unknown
- 2020-10-16 CL CL2020002680A patent/CL2020002680A1/en unknown
-
2024
- 2024-01-12 JP JP2024003062A patent/JP2024056687A/en not_active Withdrawn
-
2025
- 2025-09-18 US US19/333,297 patent/US20260015436A1/en active Pending
- 2025-12-10 JP JP2025244101A patent/JP2026062683A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016130539A2 (en) * | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| WO2017194438A1 (en) * | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
Non-Patent Citations (6)
| Title |
|---|
| CHEAL SARAH ET AL,, COMPARATIVE EFFICACY AND TOXICITY OF LU-177-VS Y-90-THERANOSTIC ANTI-HER2/ANTI-DOTA(METAL) PRETARGETED RADIOIMMUNOTHERAPY (ANTI-HER2 DOT-APRIT) OF HER2-EXPRESSING BREAST CANCER XENOGRAFTS WITH CURATIVE INTENT., 1 May 2017 (2017-05-01) * |
| CHRISTIAN KLEIN ET AL,, THE USE OF CROSSMAB TECHNOLOGY FOR THE GENERATION OF BI- AND MULTISPECIFIC ANTIBODIES, 10 June 2016 (2016-06-10) * |
| DAMIAN J. GREEN ET AL,, COMPARATIVE ANALYSIS OF BISPECIFIC ANTIBODY AND STREPTAVIDIN-TARGETED RADIOIMMUNOTHERAPY FOR B-CELL CANCERS, 2 September 2016 (2016-09-02) * |
| LARSON STEVEN M ET AL,, RADIOIMMUNOTHERAPY OF HUMAN TUMOURS., 22 May 2015 (2015-05-22) * |
| YAZAKI ET AL,, HUMANIZATION OF THE ANTI-CEA T84.66 ANTIBODY BASED ON CRYSTAL STRUCTURE DATA, 1 January 2004 (2004-01-01) * |
| YAZAKI PAUL J ET AL,, A SERIES OF ANTI-CEA/ANTI-DOTA BISPECIFIC ANTIBODY FORMATS EVALUATED FOR PRE-TARGETING: COMPARISON OF TUMOR UPTAKE AND BLOOD CLEARANCE., 21 November 2012 (2012-11-21) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277575B1 (en) | Antibodies to chelated radionuclides | |
| JP2021520832A5 (en) | ||
| JP2024056687A5 (en) | ||
| JP2021503455A5 (en) | ||
| JP2023539245A5 (en) | ||
| JP2023538945A5 (en) | ||
| JP2022512234A5 (en) | ||
| IL272747B1 (en) | Bispecific 2 + 1 contorsbodies | |
| JP2021508469A5 (en) | ||
| JP2020508655A5 (en) | ||
| HRP20201928T1 (en) | COMBINATION THERAPY WITH BISPECIFIC T-CELL ACTIVATING MOLECULA FOR CD3 AND FOLATE RECEPTOR 1 (FOLR1), AND PD-1 AXIS BINDING ANTAGONIST | |
| FI3328893T3 (en) | Bispecific antibody constructs binding mesothelin and cd3 | |
| JP2018522888A5 (en) | ||
| PE20221511A1 (en) | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | |
| JP2017504578A5 (en) | ||
| NZ595687A (en) | Anti-tnf-alpha antibodies and their uses | |
| FI3322727T3 (en) | Humanized or chimeric CD3 antibodies | |
| PE20230408A1 (en) | ANTI-LILRB1 ANTIBODY AND USES THEREOF | |
| JP2025160226A5 (en) | ||
| RU2018102803A (en) | MULTI-VALENT AND MULTI-SPECIFIC HYBRID PROTEINS BINDING WITH DR5 | |
| JP2023511376A5 (en) | ||
| IL279901B1 (en) | Antibodies containing a polypeptide inserted in the framework region 3 | |
| JP2020502233A5 (en) | ||
| JP2022540610A5 (en) | ||
| JP2021529524A5 (en) |